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Objective. Impaired baroreflex function is an early indicator of cardiovascular 
autonomic imbalance. Patients with type 2 diabetes (T2D) have decreased baroreflex 
sensitivity (BRS), however, whether the neural and/or mechanical component of the 
BRS (nBRS and mBRS, respectively) is altered in those with high metabolic risk 
(HMR, impaired fasting glucose and/or metabolic syndrome) or with overt T2D, is 
unknown. We examined this in a community-based observational study, the Paris 
Prospective Study III.  
Approach and Results. In 7626 adults aged 50 to 75 years, resting nBRS 
(estimated by low frequency gain, from carotid distension rate and RR intervals) and 
mBRS were measured by high-precision carotid echotracking. The associations 
between overt T2D or HMR as compared to subjects with normal glucose 
metabolism (NGM) and nBRS or mBRS were quantified using multivariable linear 
regression analysis. There were 319 subjects with T2D (61±6 years, 77% male), 
1450 subjects with HMR (60±6 years, 72% male) and 5857 subjects with NGM (59±6 
years, 57% male). Compared to NGM, nBRS was significantly lower in HMR subjects 
(β=-0.07, 95% CI -0.12, -0.01, p=0.029), and in subjects with T2D (β=-0.18, 95% CI -
0.29, -0.07, p=0.002) after adjustment for confounding and mediating factors. 
Subgroup analysis suggests significant and independent alteration in mBRS only 
among HMR patients who had both impaired fasting glucose and metabolic 
syndrome.  
Conclusion. In this community-based study of individuals aged 50 to 75, a graded 
decrease in nBRS was observed in HMR subjects and patients with overt T2D as 












BP, blood pressure 
BRS, baroreflex sensitivity 
eGFR, estimated glomerular filtration rate 
HMR, high metabolic risk  
IFG, impaired fasting glucose 
mBRS, mechanical baroreflex sensitivity 
MetS, metabolic syndrome 
nBRS, neural baroreflex sensitivity 
NGM, normal glucose metabolism 
PPb, brachial pulse pressure 
PPS3, Paris Prospective Study III 
RR interval, time elapsed between two successive R waves 




Arterial baroreflex plays an important role in short-term regulation of blood pressure 
(BP). Baroreflex sensitivity (BRS) is often used as an estimate of baroreflex function 
and impairment of BRS is one of the earliest indicators of cardiovascular autonomic 
imbalance often undetected by conventional clinical tests 1. Global BRS is impaired 
in patients with type 2 diabetes (T2D) 2 and depressed BRS independently predicts 
major adverse cardiovascular events in this population 3.  
 
Traditionally, fluctuations in BP and RR interval (time elapsed between two 
successive R waves) are used to assess global BRS, which is a combination of both 
the mechanical (showing the mechanical transduction of BP changes into 
baroreceptor vessel wall stretch and dependent on the stiffness of the carotid sinus 
and the aortic arch; mBRS) and neural (reflective of the transduction of baroreceptor 
stretch into sympathetic/vagal outflow and the cardiac responsiveness; nBRS) 
components of the baroreflex pathway 4. Importantly, mBRS and nBRS can be 
independently altered in several pathologies. For example, increased arterial 
stiffness can impair baroreflex function in patients with Tetralogy of Fallot 5, while on 
the other hand, the deterioration of the neural component is responsible for 
decreased global BRS in patients with end-stage liver disease 6. Furthermore, the 
age-related decline in global BRS is attributable to arterial stiffening and damaged 
neural control of the baroreflex 7, 8. However, whether the previously observed 
impairment in global BRS in patients with T2D is due to altered mBRS or nBRS (or 
both) is not well understood: data regarding mBRS parameters are controversial 9-11 
and alterations in the nBRS have not yet been directly examined.  Furthermore, 
prediabetic states such as metabolic syndrome (MetS) or impaired fasting glucose 
(IFG) may differentially influence the two components 10, 12, 13. 
 
The aim of this study was to quantify and compare mBRS and nBRS in subjects with 
normal glucose metabolism (NGM), with high metabolic risk (HMR) and in patients 
with T2D at the population level. We hypothesized that there would be a stepwise 




Patients and methods 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. 
 
Study participants and overview. This study was a cross sectional analysis of the 
Paris Prospective Study III (PPS3), an ongoing observational prospective study for 
which the detailed methods can be found elsewhere 14. Participants provided 
informed written consent and the study protocol was approved by the Ethics 
Committee of the Cochin Hospital (Paris). The study is registered in the international 
trial registry (NCT00741728). Briefly; 10,157 volunteers aged 50 to 75 years were 
recruited from a large preventative medical center, the Centre d’Investigations 
Préventives et Cliniques in Paris (France) between June 2008 and May 2012. At 
study recruitment, participants underwent a standard clinical examination, during 
which resting high-resolution carotid echotracking was performed to measure the 
components of BRS in a quiet and temperature controlled room (22 ± 1 ºC). 
Participants completed self-administered questionnaires to derive information on 
lifestyle (i.e. physical activity using the validated Baecke questionnaire 15, diet, 
smoking and alcohol consumption) and personal and family medical history. Fasting 
blood samples were taken to assess standard blood biomarkers. 
 
Definition of groups. Glucose metabolism status was determined in line with the 
current WHO recommendation 16. Normal glucose metabolism (NGM) was defined as 
fasting glucose level <110 mg/dl and as the absence of antidiabetic treatment. 
Subjects with fasting glucose level ≥110 mg/dl and <126 mg/dl and without 
hypoglycemic medication were diagnosed with IFG. T2D status was defined as 
fasting glucose level ≥126 mg/dl and/or use of oral antidiabetic drugs or insulin. We 
further subdivided the non-T2D population according to the MetS status. The WHO 
expert consensus considers MetS a premorbid state therefore subjects with 
established diabetes mellitus were excluded from this category 17. Subjects with 
MetS were diagnosed based on the harmonized MetS definition proposed by Alberti 
et al 18 and we used it according to the mentioned WHO expert consultation 17 with 
one modification. We used the cut point 110 mg/dl instead of 100 mg/dl for fasting 
glycaemia to preserve coherency with the aforementioned diagnostic criteria of the 
disorders of glucose metabolism. Patients having the MetS and/or IFG were grouped 
into a high metabolic risk group (HMR). Detailed information about our MetS criteria 
can be found in the Supplemental material.  
 
Carotid parameters measurements. All participants fasted for at least 4 hours prior 
to carotid echotracking. Subjects rested in supine position for 10 minutes before BP 
measurement and carotid artery ultrasonography. First, brachial systolic and diastolic 
BP were measured with an oscillometric method (Omron 705C). Brachial pulse 
pressure (PPb) was calculated as PPb = systolic BP – diastolic BP and mean BP as 
diastolic BP + PPb/3. Next,  common carotid artery was imaged two cm proximal to 
the carotid bulb in the longitudinal plane using a high-resolution echotracking device 
(ART.LAB®, Esaote, Maastricht, NL) with a conventional ultrasound scanner (7.5 
MHz linear array). Common carotid artery external end-diastolic diameter (Ded) and 
intima-media thickness were measured in B-mode (60 Hz, 128 radiofrequency lines), 
pulsatile distension (∆D) was measured in fast B-mode (600Hz, 14 radiofrequency 
lines). One recording of 6 sec was made both in B-mode and in fast B-mode. Then, 
one long-term recording of the common carotid artery was performed over 5 minutes 
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in fast B-mode. Carotid pulse pressure was determined using the calibration of 
carotid distension waveforms registered by echotracking as reported by Van Bortel et 
al 19. This procedure is based on the fact that the difference between mean BP and 
diastolic BP is constant throughout the large artery tree. Carotid pulse pressure (PPc) 
is calculated from PPb and the K factor at the carotid and the brachial arteries (Kc and 
Kb, respectively) as follows: PPc = PPb×Kc/Kb. Kc is defined as (D – Ded)/∆D, where D 
is the mean external diameter calculated by dividing the area under the distension 
wave by time. The calculation of the Kb is: (mean BP – diastolic BP)/PPb.  
 
Mechanical baroreflex sensitivity. Carotid stiffness representing mBRS was 
calculated using the Bramwell-Hill equation as follows: 𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦 = 𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂 𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 =
�𝟏𝟏/(𝛒𝛒 × 𝐃𝐃𝐂𝐂), where ρ is the density of blood and DC is the distensibility coefficient of 
the carotid artery 20. DC shows the relative change in lumen area during systole for a 
given pressure change and is calculated as follows: DC = ∆A/(A×PPc), where A is 
end-diastolic lumen cross-sectional area and ∆A is the change in lumen area during 
systole. The mBRS shows the local carotid pulse wave velocity in meters per second 
(m/s). It is a widely accepted and used marker of local arterial stiffness 11, 12, 20. Other 
elastic parameters of the carotid artery that represent other metrics of the mechanical 
component of BRS were also calculated (Supplemental material). 
 
Neural baroreflex sensitivity. RR intervals were derived from the time difference 
between marks placed on the foot of the carotid diameter curve over the five minutes 
time period acquired at 600 Hz. The nBRS was calculated as reported earlier 21. 
Briefly; the common carotid artery distension rate was defined as the distension 
change between 10% and 90% of the systolic rise divided by the associated rise-
time. Simultaneous beat-to-beat carotid distension, distension rate and RR interval 
were acquired for at least 300 seconds. A section of 256 heart beats was selected for 
analysis. Power spectra of distension rate and RR interval were obtained by Fast 
Fourier Transformation. Since the relationship between the variability of the stimulus 
parameter and the variability of RR intervals shows baroreflex origin in the low 
frequency band 22, 23 mean cross spectral transfer gain between distension rate and 
RR interval signals in the frequency band of 0.04-0.15 Hz defined the low-frequency 
(LF) gain and represented nBRS. Resting heart rate was also derived from the 5-
minute-long fast B-mode recording as follows: heart rate (beats/min (bpm)) = (60 
(s/min))/(mean RR interval (s/beat)). 
 
Statistical analysis. Statistics were performed with SAS software 9.4 (Statistical 
Analysis System, Cary, NC, USA). Data with normal distribution are expressed as 
mean ± SD. Variables with skewed distribution (fasting glucose and triglycerides) 
were logarithmically transformed and are presented as median (interquartile range). 
LF gain was ln-transformed as follows: nBRS, normalized units (NU) = ln(102×LF 
gain). Unadjusted test for trend across the groups using Armitage chi-square or linear 
regression for categorical and continuous variables respectively were employed. 
Multivariable linear regression with Tukey’s post hoc test was used to quantify the 
associations between the subject groups and the arterial parameters. The 
association of HMR/T2D with nBRS and mBRS was firstly adjusted for potential 
confounders (age, sex, BMI, smoking, alcohol consumption and physical activity 
score). Further adjustments were made for suspected mediators identified from the 
literature (mean BP, estimated glomerular filtration rate (eGFR), statin use, and 
additionally, mBRS in the case of nBRS, heart rate in the case of mBRS – we did not 
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adjust for heart rate when investigating nBRS due to potential collinearity). To assess 
the separate influence of abnormal glucose levels and other metabolic disturbances, 
the HMR group was then split into the 3 following subgroups including IFG alone, no 
MetS, MetS without IFG and MetS with IFG, and the analysis was adjusted for these 
3 subgroups in addition to NGM and T2D, the confounders and mediators. Several 
sensitivity analyses were conducted to assess the robustness of our findings. Firstly, 
subjects under insulin treatment (suspected to have type 1 diabetes) were excluded. 
Secondly, to address residual confounding by antihypertensive medication, analysis 
was firstly adjusted for antihypertensive medication (yes/no) and then for 
antihypertensive drugs (beta blocking agents; calcium channel blockers; agents 
acting on the renin-angiotensin system; diuretics and other antihypertensive agents). 
Thirdly, analyses were repeated using compliance coefficient, distensibility coefficient 
and Young’s elastic modulus representing other metrics of the mechanical 
component of BRS. Last, to ease international comparison with other studies, 
analyses were only adjusted for age, sex and mean BP 9, 11.  
In all analyses, the continuous variables were included in the final models in 






Study population. Supplemental Figure I shows the selection and categorization of 
the study population. Of the initial 10,157 recruited participants, 2321 had missing 
data on carotid echotracking parameters and covariates. We additionally excluded 
subjects with prior cardiovascular diseases (n = 210) to eliminate the potential 
confounding influence on mBRS and nBRS. Compared to included participants, 
those who were excluded had higher body mass index and BP and were more likely 
to smoke and take lipid lowering medication (Supplemental Table I). Our study 
population (n = 7626) consisted of three groups: subjects with NGM (n = 5857), 
subjects with HMR (IFG and/or MetS) (n = 1450), and T2D patients (n = 319). Their 
baseline characteristics are shown in Table 1. The mean age was 60 years and 40% 
of the whole population were women. Patients with HMR and those with T2D had 
significantly higher body mass index, BP and heart rate, were more likely to be men, 
take BP and lipid lowering medication and have less favourable biochemical profile 
compared to the subjects with NGM. Furthermore, nBRS decreased and mBRS 
increased significantly across the groups. The results were similar when other carotid 
elastic parameters were examined (Supplemental Table II). 
 
 
Multivariable associations between HMR and T2D with nBRS and mBRS. The 
regression coefficients and 95% CI of the multivariable association of HMR and T2D 
as compared to NGM with nBRS and mBRS are reported in Table 2, while the 
regression coefficients and 95% CI of the covariates are reported in Supplemental 
Table III and IV. After adjusting for the confounding factors and compared to NGM 
subjects, nBRS was significantly lower in T2D whereas the association was 
borderline significant in HMR subjects. Furthermore, mBRS was significantly lower in 
both HMR and T2D subjects as compared to NGM subjects. After additional 
adjustment for the mediating factors, nBRS was significantly lower in HMR subjects, 
and in subjects with T2D. Instead, the association between HMR or T2D with mBRS 
was no longer significant. In these models, in addition to HMR status and T2D, age, 
sex, body mass index, smoking, physical activity score (confounding factors), mean 
BP, eGFR and mBRS (mediating factors) were significantly associated with nBRS. 
Factors significantly associated with mBRS were age, sex, body mass index, alcohol 
consumption (confounding factors), mean BP, heart rate and eGFR (mediating 
factors) (Supplemental Table IV). 
Subgroup analysis (Table 3) further indicates that the lower nBRS in HMR subjects 
as compared to the NGM subjects was observed in HMR subjects with MetS and in 
HMR subjects with both MetS and IFG, but not in HMR subjects with IFG alone. In 
addition, the higher mBRS in HMR subjects as compared to the NGM subjects was 
observed only in those who had both the MetS and IFG. 
 
Sensitivity analysis. First, exclusion of patients treated by insulin did not change the 
main results (Supplemental Table V). Second, further adjustment for antihypertensive 
treatment (yes/no) and for antihypertensive medication classes showed essentially 
unaltered results (Supplementary Table VI and VII). Third, similar results were 
observed when other metrics of carotid stiffness (compliance coefficient, distensibility 
coefficient and Young’s elastic modulus) were used (Supplemental Table VIII). Last, 
when analyses were adjusted only for age, sex and MBP (Figure 1), nBRS 
decreased while mBRS increased linearly across the three groups (p for trend<0.001 




In this large study of community dwelling adults aged 50 to 75, nBRS was 
significantly and gradually lower in patients with HMR and in those with overt T2D 
compared to subjects with NGM independently from confounding and mediating 
factors. Impairment of mBRS in the T2D group as compared to subjects with NGM 
was explained by mediating factors such as increased blood pressure, increased 
heart rate and eGFR. Alteration in mBRS in subjects with HMR as compared to 
subjects with NGM was seen in those with both IFG and MetS in subgroup analysis.  
 
Only a few previous studies have investigated nBRS alteration in patients with 
diabetes. Ruiz et al demonstrated that neuropathy measured at the periphery is a 
more important determinant of global BRS than carotid distensibility in T2D patients 
2. Lipponen et al also showed impaired nBRS in a small group of patients (n = 15) 
with type 1 diabetes using methods similar to ours 24. However, compared to this 
earlier work, we have shown in a much larger sample size and using a method 
specifically developed for investigating the neural and mechanical components of the 
BRS separately, that nBRS is impaired in patients with T2D. Our results are obtained 
at a population level, with patients having milder presentation of the disease. The 
results of this study underline the importance of lifestyle-modification and treatment 
development in T2D patients because the therapeutic repertoire for improving 
cardiovagal neural activity is imperfect. Enhanced glucose control elicits only a 
modest reduction in neuropathy in T2D patients 25-27 in contrast to the considerable 
effect in patients with type 1 diabetes 28. Based on our results and recent results of 
another substudy of PPS3 29, regular physical activity could play an important role in 
the lifestyle-modification process. Beside other favorable effects exercise training 
improves global BRS in T2D patients 30 and ameliorates nBRS even at advanced 
ages 31. In line with earlier findings, we observed a negative association between 
elevated BP and baroreflex function 32 and a similar relationship for smoking 33. 
Accordingly, multifactorial intervention should be applied to prevent further damage 
of neural structures. As the Steno-2 study showed, progression of autonomic 
neuropathy profoundly decreased in the T2D group where an intensive multifactorial 
therapeutic approach was used with strict treatment goals in reference to glycemic 
control, weight control, control of BP, cessation of smoking, encouragement for 
performing more physical exercise and other interventions 34. This beneficial effect of 
the 7.8 years intensified treatment regarding autonomic neuropathy was still 
observable after 21.2 years of follow-up 35. Similar results were found by Gibbons et 
al when there was no observable progression in cardiovascular autonomic 
dysfunction over a 3-year-long period in patients with well controlled risk factors and 
T2D 36. Furthermore, our results reveal the importance of treatment development that 
is based on pathogenic concepts. Additionally, the recognition of early neural 
damage without any symptoms could overcome clinical inertia and elicit a proactive 
behavior in noncompliant patients 37. 
 
There are limited studies focusing on the nBRS in prediabetic states. In a substudy of 
the PPS3 (n = 2835), Zanoli et al found decreased nBRS in patients with MetS 12. 
The difference in nBRS between HMR subjects (i.e. with IFG and/or MetS) and NGM 
subjects was also significant in the present analysis after adjustment for confounders 
and mediators. In line with the previous substudy, our subgroup analysis confirmed 
that the significant and independent difference was mediated by the accumulation of 
metabolic disturbances that define metabolic syndrome and less by abnormal 
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glucose level per se. Our results are in line with the findings of Wu et al who showed 
that the state of IFG is not independently associated with baroreflex impairment 38. 
 
Earlier results regarding the association between carotid elasticity representing 
mBRS and T2D are controversial. While the Hoorn study and the Maastricht study 
showed independent association between carotid stiffening and T2D status 9, 11, the 
Asklepios study did not show a similar relationship 10. One explanation for the lack of 
independent association between T2D and mBRS in our study is that the vast 
majority of the patients included in the current study were in the very early stage of 
diabetes with only 8 patients treated with insulin in our population. We also excluded 
patients with prior cardiovascular diseases to avoid the possible influence on the 
components of BRS. A further explanation of our results could be the voluntary 
participation of the subjects in the PPS3 that could lead to a relatively health-oriented 
population. In line with these assumptions, only 4.3% of the PPS3 participants had 
T2D, which is much less than the age-specific prevalence of T2D in France 39-41. 
Last, there is a 25 years difference (from age 50 to 75) in the constitution of the 
cohort, and population characteristics might be notably different (sensitivity to risk 
factors, exposure to different treatments, evolution of socioeconomic context etc.). 
Taken together, early stage and good clinical control could explain our results 
showing that impaired carotid elastic function is not an intrinsic phenomenon of T2D 
in our population; instead, it is explained by mediating factors like increased blood 
pressure, increased heart rate or renal function. Therefore, the main focus of therapy 
and future research should be on these factors. Elevated heart rate could be the 
consequence of decreased nBRS in our T2D group. Although the underlying 
mechanism of the stiffening action of elevated heart rate is not entirely clear 42, 
improvement of neural functions could also have beneficial effects on mBRS through 
the lowering of baseline heart rate. 
 
Similar to T2D, studies examining carotid elastic parameters in prediabetic conditions 
showed controversial results 9, 10, 12, 13, 43-48. However, since diagnostic criteria of 
prediabetic states were different in these studies, it is hard to make clear conclusions 
regarding the elastic function of the carotid artery in patients with HMR. We showed 
that stiffening of the carotid artery is already present before overt T2D and that is 
likely due to mediating factors. In agreement with the results of the Rotterdam study 
we did not find an independent association between altered elastic function and IFG 
in subjects younger than 75 years 13. In contrast, we observed that subjects with the 
simultaneous presence of metabolic syndrome and IFG had significantly higher 
mBRS compared to the NGM group. This result could partially explain the findings of 
Guize et al 49. They examined the risk of short term all-cause mortality in different 
component combinations of metabolic syndrome. They found that those three-
component combinations that were associated with higher risk of all-cause mortality 
included the component of elevated glucose level in the majority of the cases. This 
finding is also in line with the results of the MARE Consortium 50. They measured 
carotid-femoral pulse wave velocity in different clusters of MetS components. They 
showed that the majority of the clusters of MetS components that were associated 
with extremely stiff arteries included the component of elevated glucose level. 
 
Statin therapy or treatment with different classes of antihypertensive drugs did not 
have substantial influence on our main results. We did not make adjustment for 
antidiabetic treatment to avoid substantial overfitting of our models. The literature 
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about the effects of antidiabetic medication on baroreflex function is limited. 
Metformin was related to improved baroreflex function in previous animal 
experiments 51, 52. Recent results of the Maastricht study showed that use of 
metformin was not associated with lower carotid stiffness 53. 
 
Our study had several strengths. We included data from a large, well-characterized 
study sample and used highly specialized and sensitive technique to measure nBRS 
and mBRS at the same site. Baroreflex sensitivity is traditionally measured using RR 
interval responses to changes in systolic BP measured at the periphery. However, 
peripheral BP values may not properly represent the pressure at the level of the 
baroreceptors due to wave propagation and wave reflection 54. Therefore, we 
measured local (carotid) blood pressure, carotid diameter and distension to calculate 
mBRS and examined the spectral relationship between carotid distension rate and 
RR interval signals to estimate nBRS. Accordingly, we received more detailed 
information about baroreflex function without the confounding effect of wave 
propagation and wave reflection which is influenced by the mechanical properties of 
peripheral arteries 54. However, there are some limitations that should be considered. 
T2D diagnosis was only based on a fasting blood glucose measure and Hemoglobin 
A1c level measurement or oral glucose tolerance test to confirm the presence of 
diabetes were not performed in the current study. We were not able to distinguish 
between type 1 and type 2 diabetes, however, since the main results did not change 
after the exclusion of patients treated with insulin (suspected to have type 1 diabetes; 
n = 8) we believe that the potential presence of a few patients with type 1 diabetes 
did not lead to draw false conclusions. The cross-sectional nature of our study limits 
inference regarding causality. The relationship between IFG, MetS and BRS is based 
on subgroup analysis and should therefore be interpreted with caution. Finally, the 
study was conducted in a predominantly caucasian population and our results should 
be examined in more ethnically diverse populations. 
 
Conclusions. This study provides a systematic comparison of neural and 
mechanical components of the BRS between subjects with NGM, subjects with HMR 
and patients with T2D. We observed a graded decrease in nBRS across NGM, HMR, 
and T2D that was independent from confounding and mediating factors. Subgroup 
analysis suggests significant and independent alteration in mBRS only in HMR 
subjects with both IFG and the MetS.  
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- In a large community-based study of over 7626 men and women aged 50 to 
75, neural baroreflex sensitivity as measured non-invasively by high-precision 
carotid echotracking decreased linearly across subjects with normal glucose 
metabolism, subjects with high metabolic risk, and patients with type 2 
diabetes independently from confounding and mediating factors.  
- Damage in the mechanical component of baroreflex sensitivity in patients with 
type 2 diabetes was due to mediating factors (increased blood pressure, 
increased heart rate, eGFR). 
- Independent alteration in the mechanical component of baroreflex sensitivity 





Figure 1. Distribution of neural baroreflex sensitivity (A), mechanical baroreflex 
sensitivity (B) in subjects with normal glucose metabolism (NGM), subjects with high 
metabolic risk (HMR) and patients with type 2 diabetes (T2D). Mean values and 95% 
confidence intervals are adjusted for age, sex and mean blood pressure. *indicates 





Table 1. Participant characteristics. 
 NGM 
(n = 5857) 
HMR 
(n = 1450) 
T2D 
(n = 319) p trend  
Age (years) 59±6 60±6‡ 61±6‡§ <0.0001 
Male, n (%)  3311 (57) 1038 (72)‡ 247 (77)‡ <0.0001 
Body mass index (kg/m2) 24.40±3.32 27.12±3.64‡ 27.70±4.14‡§ <0.0001 
Waist circumference (cm) 84.1±11.0 92.8±10.9‡ 95.3±10.9‡§ <0.0001 
Current smoker, n (%) 832 (14) 228 (16) 39 (12) 0.75 
Consume alcohol, n (%) 5167 (88) 1289 (89) 263 (82)‡§ 0.101 
Total physical activity  6.9±1.5 6.8±1.6‡ 6.6±1.6‡ <0.0001 
Systolic BP (mmHg) 129±16 136±15‡ 137±16‡ <0.0001 
Diastolic BP (mmHg) 75±9 79±10‡ 78±10‡ <0.0001 
Mean BP (mmHg) 93±11 98±10‡ 98±10‡ <0.0001 
Resting heart rate (bpm)* 68±10 71±12‡ 73±13‡§ <0.0001 
BP lowering medication, n (%) 710 (12) 343 (24)‡ 136 (43)‡§ <0.0001 
Lipid lowering medication, n (%) 560 (10) 306 (21)‡ 103 (32)‡§ <0.0001 
Glucose lowering medication, n (%) - - 169 (53) - 
Fasting glucose (mg/dl)† 97 (92, 102) 110 (101, 114)‡ 132 (120, 148)‡§ <0.0001 
Total cholesterol (mg/dl) 221.3±34.6 225.6±36.2‡ 206.5±44.0‡§ 0.0260 
HDL cholesterol (mg/dl) 61.0±14.9 51.5±14.2‡ 51.2±13.9‡ <0.0001 
LDL cholesterol (mg/dl) 142.1±30.8 147.2±32.1‡ 129.7±38.3‡§ 0.34 
Triglycerides (mg/dl)† 83 (66, 107) 125 (86, 169)‡ 113 (87, 158)‡ <0.0001 
eGFR (ml min-1 1.73 m-2) 79.11±12.71 77.43±13.19‡ 78.27±13.31 0.0002 
nBRS (NU) 2.96±0.63 2.89±0.63‡ 2.80±0.67‡ <0.0001 
mBRS (m/s) 7.0±1.3 7.4±1.4‡ 7.6±1.4‡ <0.0001 
Data are mean ± SD unless otherwise stated. *Resting heart rate was derived from 
the 5-minute-long fast B-mode recording. †Data are median (interquartile range); 
‡indicates significant difference compared to subjects with NGM; §indicates significant 
difference compared to subjects with HMR. NGM, normal glucose metabolism; HMR, 
high metabolic risk; T2D, type 2 diabetes; BP, blood pressure; HDL, high density 
lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; 




Table 2. Multivariable association between high metabolic risk (n = 1450) or 
type 2 diabetes (n = 319) with neural baroreflex sensitivity and mechanical 
baroreflex sensitivity as compared to normal glucose metabolism (n = 5857). 
 nBRS mBRS 
Adjusted for confounding 
factors*   
Normal glucose metabolism ref ref 
High metabolic risk -0.06 (-0.12, 0.00), p=0.059 0.17 (0.11, 0.23), p<0.0001 
Type 2 diabetes -0.16 (-0.28, -0.05), p=0.006 0.20 (0.09, 0.31), p=0.0003 
   
Additionally adjusted for 
mediating factors†   
Normal glucose metabolism ref ref 
High metabolic risk -0.07 (-0.12, -0.01), p=0.029 0.04 (-0.01, 0.10), p=0.12 
Type 2 diabetes -0.18 (-0.29, -0.07), p=0.002 0.08 (-0.02, 0.18), p=0.12 
Data are unstandardized regression coefficients and 95% confidence intervals. 
*Confounding factors: age, sex, body mass index, smoking, alcohol consumption, 
physical activity score. †Mediating factors: mean blood pressure, estimated 
glomerular filtration rate, statin therapy; mBRS in the case of nBRS; heart rate in the 
case of mBRS but not in the case of nBRS. The continuous variables were included 
in the models in standardized forms using z-scores. nBRS, neural baroreflex 



























Table 3. Multivariable association between subgroups of high metabolic risk (n 
= 1450) or type 2 diabetes (n = 319) with neural baroreflex sensitivity and 
mechanical baroreflex sensitivity as compared to normal glucose metabolism 
(n = 5857). 
 nBRS mBRS 
Normal glucose metabolism ref ref 
IFG, no MetS (n=420) 0.05 (-0.05, 0.14), p=0.33 -0.06 (-0.15, 0.03), p=0.17 
MetS without IFG (n=624) -0.10 (-0.18, -0.02), p=0.019 0.06 (-0.02, 0.14), p=0.11 
MetS with IFG (n=406) -0.15 (-0.25, -0.05), p=0.004 0.14 (0.05, 0.24), p=0.002 
Type 2 diabetes -0.18 (-0.30, -0.07), p=0.001 0.09 (-0.02, 0.19), p=0.095 
Age -0.16 (-0.19, -0.14), p<0.0001 0.21 (0.19, 0.24), p<0.0001 
Sex 0.08 (0.04, 0.13), p=0.0007 -0.06 (-0.10, -0.01), p=0.012 
Body mass index -0.06 (-0.09, -0.04), p<0.0001 0.10 (0.08, 0.12), p<0.0001 
Smoking -0.11 (-0.17, -0.04), p=0.001 -0.01 (-0.06, 0.05), p=0.87 
Alcohol consumption  0.05 (-0.02, 0.12), p=0.16 -0.08 (-0.14, -0.02), p=0.016 
Physical activity score 0.03 (0.01, 0.05), p=0.020 0.00 (-0.03, 0.02), p=0.75 
Mean blood pressure -0.14 (-0.16, -0.11), p<0.0001 0.30 (0.28, 0.32), p<0.0001 
Heart rate - 0.11 (0.09, 0.14), p<0.0001 
Statin use -0.04 (-0.12, 0.03), p=0.27 -0.03 (-0.10, 0.04), p=0.43 
eGFR -0.05 (-0.07, -0.03), p<0.0001 -0.07 (-0.09, -0.04), p<0.0001 
mBRS 0.25 (0.23, 0.28), p<0.0001 - 
Data are unstandardized regression coefficients and 95% confidence intervals. The 
continuous variables were included in the models in standardized forms using z-
scores. Analysis was adjusted for the variables included in the Table. nBRS, neural 
baroreflex sensitivity; mBRS, mechanical baroreflex sensitivity; IFG, impaired fasting 
glucose; MetS, metabolic syndrome; eGFR, estimated glomerular filtration rate. 
 
 
 
